Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis

REPRODUCTIVE BIOMEDICINE ONLINE

卷:33

Article

Griesinger, Georg¹  Boostanfar, Robert²  Gordon, Keith³  Gates, Davis³  Sisk, Christine McCrary³  Stegmann, Barbara J.³ 

[1] Univ Clin Schleswig Holstein, Dept Reprod Med & Gynecol Endocrinol, Campus Luebeck, Lubeck, Germany

[2] Huntington Reprod Ctr, Encino, CA USA

[3] Merck & Co Inc, Kenilworth, NJ 07033 USA

关键词: corifollitropin alfa;    GnRH antagonist;    ovarian hyperstimulation syndrome;    ovarian stimulation;    pregnancy;   

DOI  :  10.1016/j.rbmo.2016.04.005

来源: Elsevier

【 摘 要 】

A meta-analysis was conducted of individual patient data (n = 3292) from three randomized controlled trials of corifollitropin alfa versus rFSH: Engage (150 mu g corifollitropin alfa n = 756; 200 IU rFSH n = 750), Ensure (100 mu g corifollitropin alfa n = 268; 150 IU rFSH n = 128), and Pursue (150 mu g corifollitropin alfa n = 694; 300 IU rFSH n = 696). Women with regular menstrual cycles aged 18-36 and body weight >60 kg (Engage) or <= 60 kg (Ensure), or women aged 35-42 years and body weight >= 50 kg (Pursue), received a single injection (100 mu g or 150 mu g) of corifollitropin alfa (based on body weight and age) or daily rFSH. The difference (corifollitropin alfa minus rFSH) in the number of oocytes retrieved was +1.0 (95% CI: 0.5-1.5); vital pregnancy rate: -2.2% (95% CI: -5.3%-0.9%); ongoing pregnancy rate: -1.7% (95% CI: -4.7%-1.4%); and live birth rate: -2.0% (95% CI: -5.0%-1.1%). The odds ratio for overall OHSS was 1.15 (95% CI: 0.82-1.61), and for moderate-to-severe OHSS: 1.29 (95% CI: 0.81-2.05). A single dose of corifollitropin alfa for the first 7 days of ovarian stimulation is a generally well-tolerated and similarly effective treatment compared with daily rFSH. (C) 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

【 授权许可】

Free